[ad_1]
Key analysis and exclusive content under the tree. You can even give someone a last-minute gift with a one-year subscription to Portfolio Signature. And if you buy an annual subscription for multiple friends, friends and family at the same time, you can also get a quantity discount. So in addition to being a useful gift for the holidays, it can even support the production of quality inexpensive content. Know more
The two researchers, Özlem Türeci and Ugur Sahin, are oncologists specialized in immunotherapy. His name was released on November 9, when a vaccine developed jointly by the research company they founded, BioNTech, and the US pharmaceutical company Pfizer, made a breakthrough in the global fight against the coronavirus epidemic. The BNT162b2 vaccine, developed in Mainz, has been shown to be effective in more than 90 percent of clinical trials, providing protection for almost all those vaccinated. A total of 1.3 billion doses of the vaccine are planned to be marketed worldwide.
According to Sahin, the coronavirus can be immunologically controlled, as evidenced by its 95 percent efficiency, as well as antibody and T-cell reactions. The diversity of immune responses is especially important when the virus continues to mutate.
As far as they know, the vaccine is also effective against a significantly more contagious mutant discovered in Britain.
However, tests are still under way to determine if it is suitable for neutralizing multiple mutants.
However, according to Türeci, in case of a strong mutation of the virus, it is possible to “personalize” the vaccine, that is, to replace the genetic information of the current viral antigens with the new mutated viruses. This process would take six weeks, he added.
The researchers hope that the duration of protection from vaccination will be the same as the duration of natural protection from other infections. Protection can be further increased with the second vaccine, and an even greater effect is expected with a third vaccine, possibly a year later. The type of vaccine that can be stored at higher temperatures is expected to be on the market in late summer. This is because the current vaccine, co-produced with Pfizer, must be stored at minus 70 degrees.
[ad_2]
